Employers need prices they can trace to payments, Nomi and Leap leaders argue
A benefits discussion challenged cost shifting and put the mechanics of purchasing care at the center of the affordability debate.
Knowing a healthcare price is of limited use if an employer cannot connect it to the claim it paid or act before the next renewal. That was the purchasing problem Mark Newman and Robert LaHayne put at the center of a November 17 discussion about employer affordability: transparency has to change a transaction, not simply produce another report.
“Transparency without traceability is a lie,” said Newman, Nomi Health’s founder and CEO. He argued that employers need timely information that links stated prices, actual claims and member responsibility, alongside the ability to change how they purchase care. His challenge was aimed at the distance between observing spending and controlling it.
Newman and LaHayne, co-founder and chief commercial officer of Leap, spoke in The Economics of Health: Who Pays, Who Benefits, and What Comes Next. Rachel (Rae) Woods, head of care delivery at Health Tech Nerds, moderated. The official agenda also listed Dr. Reetika Kumar of Independence Blue Cross; the retained discussion contains introductions and contributions from Newman and LaHayne, and does not establish a contribution from Kumar.
Cost shifting leaves the bill in the system
Woods began with the employer’s central dilemma: whether the benefits employees expect remain affordable when costs keep rising. She asked whether familiar tools, including prior authorization, step therapy and larger employee contributions, had exhausted their usefulness or left other options underused.
Newman’s answer was that much of the industry’s response has been a coping mechanism. Moving expense from the employer to the employee can change who pays without changing the underlying price of care. Woods sharpened that distinction, noting that a high-deductible design does not necessarily remove spending from the system.
LaHayne applied the same reasoning to site-of-care strategies. Moving a service from an expensive setting to a less expensive one may save money, he said, yet still leave the purchaser paying an inflated price. His argument was for examining how care is bought and sold, rather than treating every relative discount as evidence that the transaction is efficient.
That distinction matters for benefit teams asked to defend savings. A lower employer contribution, a lower total allowed amount and a lower patient bill are different outcomes. The discussion encouraged buyers to identify which measure a proposed intervention changes before treating it as a solution to affordability.
Data needs an operating mechanism
Newman described Nomi’s approach as combining analytics, provider payments and direct contracting. He said the company sought to connect knowledge of spending with movement of money and the purchase of care, rather than leaving those functions disconnected. The aim, in his account, was to give employers the infrastructure to act on what they learn.
He described a Michigan effort built around direct relationships with health systems, prompt payment and plans without copays or deductibles. Newman reported employer savings of 20% to 24% in that program. Those were company-reported figures presented in the discussion; the session did not supply the underlying analysis needed to independently establish the comparison or generalize it to other markets.
His framework had three requirements: transparency, traceability and timeliness. A published rate is the beginning; the employer must also determine whether that rate explains its own claims. Even a useful answer can arrive too late if the data come months after the decision it should inform.
“You have to solve that to actually do something about it,” Newman said of those requirements. He connected faster access to information with greater control over payments. The practical purchasing question was whether the employer can use the data to change a contract, network or workflow while the opportunity still exists.
Newman’s closing example was a demand for visibility into contract provisions that change payment on unusually large claims. His recommendation was to examine those exceptions as well as headline rates, because the apparent price may not explain the most expensive transactions.
Specialty drugs expose the baseline problem
LaHayne focused on specialty drugs paid through the medical benefit, distinguishing that category from prescriptions paid through the pharmacy benefit. He described Leap as contracting directly with employers to reduce costs and improve the patient experience in that part of the plan. The distinction is important because a pharmacy-focused strategy alone does not address every drug expense.
He used infusion billing to illustrate how a code or total charge may obscure what is being purchased. Employers need to understand the transaction beneath the claim, he argued, and then build a service capable of changing it. More detailed information does not itself create an alternative source of care.
“It's about resetting the baseline a little bit,” LaHayne said. For a patient needing treatment over several years, a lower fair price can become the starting point for future spending, rather than only a first-year return attached to a temporary intervention. He framed that as an ongoing cost-reduction strategy.
That approach also changes the evaluation of navigation and support. Woods asked how employers should assess the larger investment around a drug or service, including adherence, care management and data. The panel’s response connected financial results with reaching the person who needs help, rather than assuming an additional service earns its place merely because it is available.
Specialization does not remove employer accountability
Woods challenged the expansion of specialized vendors: do they deliver better experiences, or further fragment care? LaHayne argued that focused services can respond to problems the existing arrangement has not solved. Newman similarly defended specialist organizations addressing large, distinct areas of need, while acknowledging that the overall experience still requires an owner.
Their answer placed that responsibility with the employer. Newman connected the benefits experience with retention and the company’s relationship with its workforce. LaHayne pointed to navigation, HR partnerships and technology as ways to connect services even when different organizations deliver different parts of care.
“Own and understand your data and really push for it,” LaHayne said in his closing recommendation. He urged employers to identify the areas the data show are costly, then align incentives among vendors, providers and employees so that a proposed change can actually be used.
The discussion left a concrete test for the next purchasing cycle. A buyer should be able to trace a claimed saving to a change in price or care delivery, explain who benefits and identify who owns the member’s experience. Without those connections, more transparency can illuminate the bill while leaving the employer with the same limited choices.